Algeta enters "hot antibody" cancer collaboration with Affibody
This article was originally published in Scrip
Executive Summary
Norway’s Algeta has entered into an exclusive research, development and commercialisation agreement with Affibody of Sweden to develop tumor-targeting alpha-pharmaceuticals based on thorium-227.